Biocardia Company Insiders
BCDA Stock | USD 2.10 0.05 2.44% |
About 92 percent of all Biocardia's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Biocardia suggests that a fairly large number of insiders are very bullish. Biocardia employs about 16 people. The company is managed by 6 executives with a total tenure of roughly 18 years, averaging almost 3.0 years of service per executive, having 2.67 employees per reported executive.
Peter Altman CEO President CEO, Principal Executive Officer, Director |
David McClung President Principal Financial and Accounting Officer, Vice President - Finance |
Insider Sentiment 92
Aggressively Buying
Selling | Buying |
Latest Trades
2025-02-07 | Peter Altman | Acquired 600 @ 2.48 | View | ||
2025-01-29 | Peter Altman | Acquired 500 @ 2.4 | View | ||
2024-12-23 | Peter Altman | Acquired 1000 @ 2.06 | View | ||
2024-12-20 | Edward M Gillis | Disposed 3257 @ 2 | View | ||
2024-12-05 | Peter Altman | Acquired 250 @ 2.22 | View | ||
2024-11-15 | Peter Altman | Acquired 1350 @ 1.87 | View | ||
2024-07-01 | Peter Altman | Acquired 300 @ 3.05 | View | ||
2024-06-28 | Peter Altman | Acquired 200 @ 2.99 | View | ||
2024-06-21 | Peter Altman | Acquired 500 @ 3.29 | View | ||
2024-06-14 | Peter Altman | Acquired 500 @ 3.52 | View | ||
2024-06-10 | Peter Altman | Acquired 1000 @ 3.36 | View | ||
2024-04-19 | Peter Altman | Acquired 183 @ 5.55 | View | ||
2024-03-28 | Peter Altman | Acquired 33 @ 5.85 | View |
Monitoring Biocardia's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Biocardia |
Biocardia's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Biocardia's future performance. Based on our forecasts, it is anticipated that Biocardia will maintain a workforce of about 16 employees by March 2025.Biocardia Management Team Effectiveness
The company has return on total asset (ROA) of (0.9691) % which means that it has lost $0.9691 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.3789) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biocardia's Return On Capital Employed is projected to increase significantly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 6.82, whereas Return On Tangible Assets are projected to grow to (4.23). At present, Biocardia's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 436.7 K, whereas Total Assets are forecasted to decline to about 3.3 M.As of February 26, 2025, Common Stock Shares Outstanding is expected to decline to about 1.4 M. In addition to that, Net Loss is expected to decline to about (11.3 M)
Biocardia Workforce Comparison
Biocardia is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 819. Biocardia claims roughly 16.0 in number of employees contributing just under 2% to equities under Health Care industry.
Biocardia Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biocardia insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 2.2 | 11 | 5 | 76,017 | 59,150 |
2023-06-01 | 4.0 | 12 | 3 | 692,531 | 73,009 |
2022-06-01 | 0.3333 | 1 | 3 | 31,085 | 47,303 |
2021-06-01 | 1.5 | 9 | 6 | 376,594 | 93,703 |
2020-12-01 | 9.0 | 18 | 2 | 46,398 | 11,635 |
2020-06-01 | 10.25 | 41 | 4 | 851,772 | 36,393 |
2020-03-01 | 1.1429 | 8 | 7 | 10,201 | 12,469 |
2019-12-01 | 1.6667 | 5 | 3 | 10,100 | 30,000 |
2019-09-01 | 2.1429 | 30 | 14 | 822,449 | 641,825 |
2019-03-01 | 1.25 | 5 | 4 | 2,318 | 2,268 |
2018-12-01 | 9.6667 | 29 | 3 | 15,523,445 | 833,333 |
2018-06-01 | 1.5 | 6 | 4 | 40,664 | 36,664 |
2018-03-01 | 4.0 | 16 | 4 | 918,594 | 20,444 |
2017-12-01 | 1.0 | 4 | 4 | 1,630,716 | 1,630,716 |
2016-12-01 | 0.1 | 2 | 20 | 172,600 | 39,853,037 |
2016-06-01 | 0.25 | 1 | 4 | 114,937,148 | 103,917,532 |
2011-06-01 | 3.0 | 3 | 1 | 127,185 | 0.00 |
2008-09-01 | 0.15 | 3 | 20 | 28,016,949 | 1,565,000 |
2005-03-01 | 0.25 | 1 | 4 | 600,000 | 84,490 |
Biocardia Notable Stakeholders
A Biocardia stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biocardia often face trade-offs trying to please all of them. Biocardia's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biocardia's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Peter Altman | President CEO, Principal Executive Officer, Director | Profile | |
David McClung | Principal Financial and Accounting Officer, Vice President - Finance | Profile | |
Edward Gillis | Senior Devices | Profile | |
Ian McNiece | Chief Officer | Profile | |
Sujith Shetty | Chief Regulatory | Profile | |
Sujith MBBS | Chief Regulatory | Profile |
About Biocardia Management Performance
The success or failure of an entity such as Biocardia often depends on how effective the management is. Biocardia management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biocardia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biocardia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (4.45) | (4.23) | |
Return On Capital Employed | 16.88 | 17.72 | |
Return On Assets | (4.45) | (4.23) | |
Return On Equity | 6.50 | 6.82 |
Please note, the presentation of Biocardia's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biocardia's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biocardia's management manipulating its earnings.
Biocardia Workforce Analysis
Traditionally, organizations such as Biocardia use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biocardia within its industry.Biocardia Manpower Efficiency
Return on Biocardia Manpower
Revenue Per Employee | 29.8K | |
Revenue Per Executive | 79.5K | |
Net Loss Per Employee | 723.2K | |
Net Loss Per Executive | 1.9M |
Complementary Tools for Biocardia Stock analysis
When running Biocardia's price analysis, check to measure Biocardia's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocardia is operating at the current time. Most of Biocardia's value examination focuses on studying past and present price action to predict the probability of Biocardia's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocardia's price. Additionally, you may evaluate how the addition of Biocardia to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |